Life AI Net
홈
아카이브
계산기
디렉토리
뉴스레터
로그인
한국어
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
홈
아카이브
계산기
디렉토리
뉴스레터
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
로그인
홈
아카이브
계산기
디렉토리
More
실시간
BioPharma Dive
Merck still sees ‘compelling’ outlook for Terns leukemia drug
Cell
Proteostasis sustains T cell differentiation potential and tumor-infiltrating lymphocyte function
Cell
Differential inhibition of <em>Morbillivirus</em> and <em>Henipavirus</em> polymerases by ERDRP-0519 and structure-guided inhibitor optimization
BioPharma Dive
UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy
Endpoints News
Avalyn's upsized IPO; Alector ends another study in GSK partnership
Endpoints News
Analysts focus on three programs in big year for Bristol Myers
BioPharma Dive
Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch
Endpoints News
XTL Bio to acquire psychedelic biotech; WuXi AppTec’s Q1 revenue rise
Lonza News
High-throughput chromatography in bioprocess analytics - News-Medical
FierceBiotech
Indivior warns of ‘significant impact’ on R&D team after opioid use disorder drug fails phase 2
FierceBiotech
BMS calls time on Zymeworks collab, ending work on phase 1 cancer bispecific
Endpoints News
What we heard at a health tech conference in Boston
BioPharma Dive
Merck still sees ‘compelling’ outlook for Terns leukemia drug
Cell
Proteostasis sustains T cell differentiation potential and tumor-infiltrating lymphocyte function
Cell
Differential inhibition of <em>Morbillivirus</em> and <em>Henipavirus</em> polymerases by ERDRP-0519 and structure-guided inhibitor optimization
BioPharma Dive
UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy
Endpoints News
Avalyn's upsized IPO; Alector ends another study in GSK partnership
Endpoints News
Analysts focus on three programs in big year for Bristol Myers
BioPharma Dive
Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch
Endpoints News
XTL Bio to acquire psychedelic biotech; WuXi AppTec’s Q1 revenue rise
Lonza News
High-throughput chromatography in bioprocess analytics - News-Medical
FierceBiotech
Indivior warns of ‘significant impact’ on R&D team after opioid use disorder drug fails phase 2
FierceBiotech
BMS calls time on Zymeworks collab, ending work on phase 1 cancer bispecific
Endpoints News
What we heard at a health tech conference in Boston
아카이브
Promega Blog
2026년 4월 30일
The Filter You Didn’t Choose
The Filter You Didn’t Choose
원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.